The present invention provides novel pyrrolo[2,1-c][1,4]benzodiazepine-glycoside prodrug of general formula 1a-b, useful as selective anticancer agents. The present invention also provides a process for the preparation of novel pyrrolo[2,1-c][1,4]benzodiazepine-glycoside prodrugs of general formula 1a-b. This invention also provides activation of these produgs by
E. coli
β galactosidase and envisaged that these molecules are toxic to human cancer cell lines in the presence of the enzyme
E. coli
β-galactosidase. The prodrugs 1a and 1b were also found to be toxic to human cancer HepG2 cells even in the absence of the
E. coli
□-galactosidase. The toxic effect of the molecules when activated was similar to that of the parent molecules 6a and 6b, respectively.
本发明提供了一种新型
吡咯并[2,1-c][1,4]苯二氮杂环糖苷前药,其通用公式为1a-b,可作为选择性抗癌剂。本发明还提供了一种制备新型
吡咯并[2,1-c][1,4]苯二氮杂环糖苷前药的方法,其通用公式为1a-b。本发明还提供了通过大肠杆菌
β-半乳糖苷酶激活这些前药,并预期这些分子在大肠杆菌
β-半乳糖苷酶存在的情况下对人类癌
细胞系具有毒性。前药1a和1b甚至在没有大肠杆菌
β-半乳糖苷酶的情况下也被发现对人类癌细胞HepG2具有毒性。当被激活时,这些分子的毒性效果类似于相应的母体分子6a和6b。